Opportunities and challenges lay ahead along the continuum from traditional to hybrid studies, a transition which requires additional infrastructure and associated risks to data protection and patient safety.
Choosing where to conduct a global clinical trial is a critical strategic decision that can impact an entire drug development program. When it comes to planning country selection, Fortuna Eruditis Favet (“fortune favors the prepared mind”).
Sites are dynamic environments, and new technology and industry initiatives are an important complement to the critical need for relationship building and maintenance. But are they helping improve sponsors and CROs collaboration with sites, or enabling them to become more competitive through improved clinical trial performance?